Primary Care Diabetes
Volume 3, Issue 3 , Pages 141-148 , August 2009

Health, treatment and health care resources consumption profile among Spanish adults with diabetes and chronic obstructive pulmonary disease

  • Rodrigo Jimenez-Garcia

      Affiliations

    • Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Avda. de Atenas s/n, 28922 Alcorcón, Madrid, Spain
    • ,
  • Javier de Miguel-Díez

      Affiliations

    • Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
    • Corresponding Author InformationCorresponding author at: Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain.
    • ,
  • Javier Rejas-Gutierrez

      Affiliations

    • Departamento Médico Pfizer España, Alcobendas (Madrid), Spain
    • ,
  • Antonio Martín-Centeno

      Affiliations

    • Departamento Médico Pfizer España, Alcobendas (Madrid), Spain
    • ,
  • Elena Gobartt-Vázquez

      Affiliations

    • Departamento Médico Boehringer Ingelheim España, San Cugat del Vallés (Barcelona), Spain
    • ,
  • Valentin Hernandez-Barrera

      Affiliations

    • Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Avda. de Atenas s/n, 28922 Alcorcón, Madrid, Spain
    • ,
  • Angel Gil de Miguel

      Affiliations

    • Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Avda. de Atenas s/n, 28922 Alcorcón, Madrid, Spain
    • ,
  • Pilar Carrasco-Garrido

      Affiliations

    • Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Avda. de Atenas s/n, 28922 Alcorcón, Madrid, Spain

Received 18 November 2008 ,Revised 31 May 2009 ,Accepted 16 June 2009.

References 

  1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008;32:962–969
  2. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478–2484
  3. Loukides S, Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration. 1996;63:170–173
  4. Antonelli IR, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997;10:2794–2800
  5. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 1999;353:1649–1652
  6. Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 1999;245:621–625
  7. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  8. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. 2001;34(Suppl.):50S–59S
  9. Festa A, D’Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131–1137
  10. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC) potsdam study. Diabetes. 2003;52:812–817
  11. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study 1984–1998. Arch. Intern. Med. 2003;163:93–99
  12. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700
  13. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur. Respir. J. 2004;22(Suppl. 46):76S–80S
  14. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity—a common inflammatory phenotype?. Respir. Res. 2006;7:70
  15. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284–289
  16. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, et al. Insulin resistance and inflammation—a further systemic complication of COPD. COPD. 2007;4:121–126
  17. García Carballo M, Carrasco Garrido P, Jiménez García R, Martín A, Gobartt E, Gil A. Estudio epidemiológico para valorar la calidad de vida y el consumo de recursos sanitarios en los pacientes con enfermedad pulmonar obstructiva crónica (EPIDEPOC). Metodología y resultados iniciales. Med. Gen. 2004;67:485–490
  18. Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, Martín Centeno A, Gobartt Vázquez E, Gil de Miguel A, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual. Life Outcomes. 2006;4:31
  19. Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, et al. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch. Bronconeumol. 2001;37:297–316
  20. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey, construction of scales and preliminary tests of realiabity and validity. Med. Care. 1996;34:220–233
  21. Instituto Nacional de Estadística. http://www.ine.es.
  22. Lazarus R, Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the normative aging study. Eur. Respir. J. 1998;12:641–645
  23. Engstrom G, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet. Med. 2002;19:167–170
  24. Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J. Intern. Med. 2003;253:574–581
  25. Litonjua AA, Lazarus R, Sparrow D, DeMolles D, Weiss ST. Lung function in type 2 diabetes: the normative aging study. Respir. Med. 2005;99:1583–1590
  26. De Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch. Bronconeumol. 2008;44:233–238
  27. Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006;21:803–813
  28. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005;1:CD001288
  29. Sicras-Mainar A, Velasco-Velasco S, Llopart-López JR, Navarro-Artieda R, de Haro-Martí L. Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population. Aten. Primaria. 2007;39:547–555
  30. Sinclair AJ, Conroy SP, Bayer AJ. Impact of diabetes on physical function in older people. Diabetes Care. 2008;31:233–235
  31. Wouters EF. Chronic obstructive pulmonary disease. Systemic effects of COPD. Thorax. 2002;57:1067–1070
  32. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc. Nutr. Soc. 1999;58:321–328
  33. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur. Respir. J. 2003;46(Suppl.):81S–86S
  34. Mador MJ. Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002;166:787–789
  35. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819–824
  36. Vermeeren MA, Schols AM, Wouters EF. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur. Respir. J. 1997;10:2264–2269
  37. Barnes PJ. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000;343:269–280
  38. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J. Biochem. Mol. Biol. 2003;36:95–109
  39. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem. 2002;234–248
  40. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 2001;17:189–212
  41. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J. Clin. Invest. 2004;114:1187–1195
  42. Venmans LM, Bont J, Gorter KJ, Verheij TJ, Rutten GE, Hak E. Prediction of complicated lower respiratory tract infections in older patients with diabetes. Br. J. Gen. Pract. 2008;58:564–568
  43. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS. Immunol. Med. Microbiol. 1999;26:259–265
  44. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik ChS , Brondum E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir. Res. 2006;7:109
  45. Almagro P, Calbo E, Ochoa de Echagen A, Barreiro B, Quintana S, Heredia JL</ET-AL>. Mortality after hospitalization for COPD. Chest. 2002;121:1441–1448
  46. Groenewegen KH, Schols AM, Wouters EFM. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–467
  47. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing. 2002;31:137–140
  48. Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA, Villasante C, Masa JF, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981–989
  49. Marco JL, Martin Berra JC, Corres IM, Luque DR, Zubillaga GG. Chronic obstructive lung disease in the general population, an epidemiologic study performed in Guipuzcoa. Arch. Bronconeumol. 1998;34:23–27
  50. Brotons B, Perez JA, Sanchez-Toril F, Soriano S, Hernandez J, Belenguer JL. The prevalence of chronic obstructive pulmonary disease and asthma, a cross-sectional study. Arch. Bronconeumol. 1994;30:149–152

PII: S1751-9918(09)00047-3

doi: 10.1016/j.pcd.2009.06.005

Primary Care Diabetes
Volume 3, Issue 3 , Pages 141-148 , August 2009

Article Tools